Show simple item record

dc.contributor.authorTala, Ilonaen_US
dc.contributor.authorChen, Ruen_US
dc.contributor.authorHu, Tinghuien_US
dc.contributor.authorFitzpatrick, Ethan Ren_US
dc.contributor.authorWilliams, David Aen_US
dc.contributor.authorWhitehead, Ian Pen_US
dc.date.accessioned2014-03-11T13:53:46Z
dc.date.issued2014en_US
dc.identifier.citationTala, Ilona, Ru Chen, Tinghui Hu, Ethan R Fitzpatrick, David A Williams, and Ian P Whitehead. 2014. “Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.” Leukemia 27 (5): 1080-1089. doi:10.1038/leu.2012.351. http://dx.doi.org/10.1038/leu.2012.351.en
dc.identifier.issn0887-6924en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879884
dc.description.abstractWe have previously identified a tyrosine kinase-independent, guanine nucleotide exchange factor (GEF) activity that is contained within the region of p210 BCR/ABL that distinguishes it from p190 BCR/ABL. In the current study we have compared the transforming activity of p190 BCR/ABL, p210 BCR/ABL, and a mutant that lacks GEF activity (p210 BCR/ABL(S509A)). In cell-based, ex vivo, and murine bone marrow transplantation assays (BMT) the transforming activity of p210 BCR/ABL(S509A) mimics p190 BCR/ABL, and is distinct from p210 BCR/ABL. Thus, in the BMT assay, the p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted mice exhibit a more rapid onset of disease than mice transplanted with p210 BCR/ABL. The reduced disease latency is associated with erythroid hyperplasia in the absence of anemia, and expansion of the MEP, CMP and GMP populations, producing a phenotype that is similar to acute myeloid leukemia (AML-M6). The disease phenotype is readily transplantable into secondary recipients. This is consistent with ex vivo clonogenicity assays where p210 BCR/ABL preferentially supports the growth of CFU-GM, while p190 BCR/ABL and the mutant preferentially support the growth of BFU-E. These results suggest that the GEF activity that distinguishes p210 BCR/ABL from p190 BCR/ABL actively regulates disease progression.en
dc.language.isoen_USen
dc.relation.isversionofdoi:10.1038/leu.2012.351en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931524/pdf/en
dash.licenseLAAen_US
dc.subjectChronic myelogenous leukemiaen
dc.subjectp210 BCR/ABLen
dc.subjectRhoGEF domainen
dc.subjectRho GTPaseen
dc.titleContributions of the RhoGEF activity of p210 BCR/ABL to disease progressionen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalLeukemiaen
dash.depositing.authorWilliams, David Aen_US
dc.date.available2014-03-11T13:53:46Z
dc.identifier.doi10.1038/leu.2012.351*
dash.contributor.affiliatedWilliams, David


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record